

# Jacob D Soumerai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3862071/publications.pdf>

Version: 2024-02-01

63  
papers

2,285  
citations

361388

20  
h-index

214788

47  
g-index

63  
all docs

63  
docs citations

63  
times ranked

2751  
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180. <i>Journal of Clinical Oncology</i> , 2009, 27, 3830-3835.	1.6	265
2	The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. <i>Blood</i> , 2020, 135, 1912-1915.	1.4	253
3	Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. <i>Blood</i> , 2019, 133, 2212-2221.	1.4	207
4	Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside Analogs. <i>Journal of Clinical Oncology</i> , 2009, 27, 250-255.	1.6	170
5	Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. <i>Blood</i> , 2009, 113, 3673-3678.	1.4	141
6	Thalidomide and rituximab in Waldenström macroglobulinemia. <i>Blood</i> , 2008, 112, 4452-4457.	1.4	135
7	Diagnosis and Management of Castleman Disease. <i>Cancer Control</i> , 2014, 21, 266-278.	1.8	127
8	Lenalidomide and Rituximab in Waldenström's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2009, 15, 355-360.	7.0	124
9	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020, 10, 74.	6.2	81
10	Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. <i>Leukemia and Lymphoma</i> , 2014, 55, 538-543.	1.3	74
11	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. <i>Blood</i> , 2022, 139, 1794-1806.	1.4	66
12	Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. <i>American Journal of Hematology</i> , 2007, 82, 83-84.	4.1	64
13	Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 62-66.	1.4	63
14	Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. <i>Lancet Haematology</i> , 2019, 6, e366-e374.	4.6	49
15	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e879-e890.	4.6	48
16	The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. <i>American Journal of Hematology</i> , 2016, 91, E436-41.	4.1	44
17	Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. <i>Blood</i> , 2011, 118, 276-281.	1.4	42
18	IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenström's Macroglobulinemia (WM). <i>Blood</i> , 2006, 108, 228-228.	1.4	28

#	ARTICLE	IF	CITATIONS
19	Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients. <i>Blood</i> , 2020, 136, 40-41.	1.4	26
20	Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. <i>Blood</i> , 2019, 134, 503-503.	1.4	24
21	The HMGâ€CoA inhibitor, simvastatin, triggers <i>in vitro</i> antiâ€tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , 2008, 142, 775-785.	2.5	21
22	Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. <i>Blood</i> , 2009, 113, 626-634.	1.4	20
23	Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. <i>British Journal of Haematology</i> , 2009, 145, 59-63.	2.5	17
24	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	7.0	17
25	Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. <i>Blood</i> , 2018, 132, 300-300.	1.4	17
26	Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. <i>Blood Advances</i> , 2022, , .	5.2	14
27	Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kÎ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies. <i>Blood</i> , 2018, 132, 2893-2893.	1.4	13
28	Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome. <i>Blood</i> , 2020, 136, 46-47.	1.4	13
29	Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. <i>Leukemia and Lymphoma</i> , 2019, 60, 1438-1446.	1.3	12
30	Results of the PI3KÎ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7512-7512.	1.6	12
31	Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen). <i>Blood</i> , 2021, 138, 3540-3540.	1.4	12
32	Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstromâ€™s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.. <i>Blood</i> , 2006, 108, 2765-2765.	1.4	10
33	Tolerability and durable responses of the PI3KÎ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8016-8016.	1.6	8
34	Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. <i>Blood</i> , 2022, 140, 1822-1826.	1.4	8
35	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2008, 112, 832-832.	1.4	7
36	Long Term Responses to Fludarabine and Rituximab in Waldenstromâ€™s Macroglobulinemia. <i>Blood</i> , 2008, 112, 3057-3057.	1.4	7

#	ARTICLE	IF	CITATIONS
37	Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib. <i>Blood</i> , 2021, 138, 1419-1419.	1.4	7
38	A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL. <i>Blood</i> , 2019, 134, 1763-1763.	1.4	6
39	Phase I study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2931-2938.	1.3	4
40	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. <i>Blood</i> , 2016, 128, 2955-2955.	1.4	4
41	Alcohol use and health care utilization in rural Liberia: Results of a community-based survey for basic public health indicators. <i>The International Journal of Alcohol and Drug Research</i> , 2014, 3, 169-181.	0.9	4
42	Imatinib Mesylate (Gleevec®) Produces Responses in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2007, 110, 2575-2575.	1.4	3
43	Abnormalities in Lipoprotein Metabolism Provide Insight into Novel Therapeutic Approaches for Waldenstrom's Macroglobulinemia (WM). <i>Blood</i> , 2006, 108, 4749-4749.	1.4	2
44	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. <i>Blood</i> , 2007, 110, 4496-4496.	1.4	2
45	Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed. <i>Blood</i> , 2016, 128, 1777-1777.	1.4	2
46	Imatinib Mesylate (Gleevec®) Is Active in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-140. <i>Blood</i> , 2006, 108, 2484-2484.	1.4	2
47	The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, , 1-10.	1.3	2
48	Case 7-2019: A 73-Year-Old Woman with Swelling of the Right Groin and Fever. <i>New England Journal of Medicine</i> , 2019, 380, 859-868.	27.0	1
49	Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2939-2946.	1.3	1
50	Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenstrom's Macroglobulinemia: Preliminary Results. <i>Blood</i> , 2007, 110, 4493-4493.	1.4	1
51	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience. <i>Blood</i> , 2008, 112, 1011-1011.	1.4	1
52	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. <i>Blood</i> , 2007, 110, 4494-4494.	1.4	1
53	Comparative Outcomes Following CP-R, CVP-R and CHOP-R in Patients with Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2008, 112, 2011-2011.	1.4	1
54	Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence. <i>Blood</i> , 2021, 138, 3753-3753.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Case 16-2022: A 55-Year-Old Man with Fevers, Night Sweats, and a Mediastinal Mass. <i>New England Journal of Medicine</i> , 2022, 386, 2036-2048.	27.0	1
56	Endoplasmic Reticulum Stress Is a Target for Therapy in Waldenstrom's Macroglobulinemia (WM).. <i>Blood</i> , 2006, 108, 4641-4641.	1.4	0
57	Abnormal Expression of TRAF Adapter Proteins in Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2006, 108, 4640-4640.	1.4	0
58	Cholesterol Regulation and Statin Therapy in Patients with Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2009, 114, 4789-4789.	1.4	0
59	Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 2691-2691.	1.4	0
60	Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era. <i>Blood</i> , 2016, 128, 4119-4119.	1.4	0
61	Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy. <i>Blood</i> , 2018, 132, 4394-4394.	1.4	0
62	Time to Second Treatment As a Proxy for Overall Survival in CLL/SLL: Identifying Risk Factors to Help Guide Treatment Selection. <i>Blood</i> , 2019, 134, 4299-4299.	1.4	0
63	Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2020, 136, 15-16.	1.4	0